Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes ...

Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC). Determining an ...

For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

Real-world data from the EV-301 trial (NCT03474107), presented at the ASCO 2025 Genitourinary Cancers Symposium, showed that third-line treatment with enfortumab vedotin (Padcev) significantly ...

Real-world analysis of the efficacy and safety of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: A multicenter retrospective study. Disease management costs ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

For localized upper tract urothelial carcinoma, there are important considerations for deciding whether a patient ... Eligible patients had non metastatic, high-grade disease on ureteroscopic tumor ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options. CASE SUMMARY A man ...

A NEW STUDY has demonstrated the clinical utility of circulating tumour DNA (ctDNA) analysis as an alternative to tissue biopsy for genotyping in advanced urothelial cancer (UC). Researchers aimed to ...